Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program for PASC Program to Improve Functioning of Persons Suffering From Post-COVID-19 Syndrome: A Randomized Controlled Trial
Launched by UNIVERSITY OF PENNSYLVANIA · Nov 28, 2023
Trial Information
Current as of September 12, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study tests whether a structured, multidisciplinary rehabilitation program can help people with Post-Acute Sequelae of SARS-CoV-2 infection (PASC, also called Long COVID) improve function, especially walking ability and daily activities. In this randomized trial, participants are assigned by chance to either Comprehensive Rehabilitation—12 one-hour sessions over six weeks that combine physical and speech therapy and are tailored to each person’s needs—or Augmented Usual Care, which includes usual care plus a baseline assessment result review and a self-management guide. The main outcome is how far participants can walk in six minutes, measured at about 1 week and 8 weeks after starting, with additional checks of thinking skills, fatigue, pain, mood, and daily functioning.
Who can participate: adults 18 and older who previously had COVID-19 and still have symptoms not explained by another cause (for example fatigue or cognitive symptoms) and who can speak English or Spanish. People who are in another clinical trial or who have very severe cognitive impairment or cannot participate in the program may not be eligible. If you join, you’ll first have a baseline assessment and then be randomly assigned to either Comprehensive Rehabilitation or Augmented Usual Care, with the person measuring outcomes not knowing which group you’re in. The study is led by the University of Pennsylvania with collaborators, plans to enroll about 216 people, and results will help guide rehabilitation options for Long COVID.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years if age or older
- • English or Spanish speaking
- • Previously tested positive for COVID
- • Still having symptoms not explained by any other etiologies
- • Cognitive impairment
- • Fatigue
- Exclusion Criteria:
- • Participation in another clinical trial
- • Score greater than 12 on the fatigue scale
- • Score greater than 30 on the memory/thinking scale
- • Severe cognitive impairment (i.e. Alzheimer's, Dementia)
- • Mental or physical inability to participate in the program
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Timothy Dillingham, MD, MS
Principal Investigator
University of Pennsylvania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported